Uptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005

Demand, supply and seasonality

Suchita A. Lorick, Daniel Fishbein, Eric Weintraub, Pascale M. Wortley, Grace M. Lee, Fangjun Zhou, Robert Davis

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: In February 2005, the US Advisory Committee on Immunization Practices recommended the new meningococcal conjugate vaccine (MCV4) for routine use among 11- to 12-year-olds (at the preadolescent health-care visit), 14- to 15-year-olds (before high-school entry), and groups at increased risk. Vaccine distribution started in March; however, in July, the manufacturer reported inability to meet demand and widespread MCV4 shortages were reported. Our objectives were to determine early uptake patterns among target (11-12 and 14-15 year olds) and non-target (13- plus 16-year-olds) age groups. A post hoc analysis was conducted to compare seasonal uptake patterns of MCV4 with polysaccharide meningococcal (MPSV4) and tetanus diphtheria (Td) vaccines.Methods: We analyzed data for adolescents 11-16 years from five managed care organizations participating in the Vaccine Safety Datalink (VSD). For MCV4, we estimated monthly and cumulative coverage during 2005 and calculated risk ratios. For MPSV4 and Td, we combined 2003 and 2004 data and compared their seasonal uptake patterns with MCV4.Results: Coverage for MCV4 during 2005 among the 623,889 11-16 years olds was 10%. Coverage for 11-12 and 14-15 year olds was 12% and 11%, respectively, compared with 8% for 13- plus 16-year-olds (p < 0.001). Of the 64,272 MCV4 doses administered from March-December 2005, 73% were administered June-August. Fifty-nine percent of all MPSV4 doses and 38% of all Td doses were administered during June-August.Conclusion: A surge in vaccine uptake between June and August was observed among adolescents for MCV4, MPSV4 and Td vaccines. The increase in summer-time vaccinations and vaccination of non-targeted adolescents coupled with supply limitations likely contributed to the reported shortages of MCV4 in 2005.

Original languageEnglish (US)
Article number175
JournalBMC Infectious Diseases
Volume9
DOIs
StatePublished - Nov 3 2009

Fingerprint

Meningococcal Vaccines
Conjugate Vaccines
Managed Care Programs
Diphtheria-Tetanus Vaccine
Diphtheria
Vaccines
Tetanus
Organizations
Vaccination
Advisory Committees
Polysaccharides
Immunization
Age Groups
Odds Ratio
Delivery of Health Care
Safety

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Cite this

Uptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005 : Demand, supply and seasonality. / Lorick, Suchita A.; Fishbein, Daniel; Weintraub, Eric; Wortley, Pascale M.; Lee, Grace M.; Zhou, Fangjun; Davis, Robert.

In: BMC Infectious Diseases, Vol. 9, 175, 03.11.2009.

Research output: Contribution to journalArticle

Lorick, Suchita A. ; Fishbein, Daniel ; Weintraub, Eric ; Wortley, Pascale M. ; Lee, Grace M. ; Zhou, Fangjun ; Davis, Robert. / Uptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005 : Demand, supply and seasonality. In: BMC Infectious Diseases. 2009 ; Vol. 9.
@article{361a8ace34a345bc965582f0b103c9d0,
title = "Uptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005: Demand, supply and seasonality",
abstract = "Background: In February 2005, the US Advisory Committee on Immunization Practices recommended the new meningococcal conjugate vaccine (MCV4) for routine use among 11- to 12-year-olds (at the preadolescent health-care visit), 14- to 15-year-olds (before high-school entry), and groups at increased risk. Vaccine distribution started in March; however, in July, the manufacturer reported inability to meet demand and widespread MCV4 shortages were reported. Our objectives were to determine early uptake patterns among target (11-12 and 14-15 year olds) and non-target (13- plus 16-year-olds) age groups. A post hoc analysis was conducted to compare seasonal uptake patterns of MCV4 with polysaccharide meningococcal (MPSV4) and tetanus diphtheria (Td) vaccines.Methods: We analyzed data for adolescents 11-16 years from five managed care organizations participating in the Vaccine Safety Datalink (VSD). For MCV4, we estimated monthly and cumulative coverage during 2005 and calculated risk ratios. For MPSV4 and Td, we combined 2003 and 2004 data and compared their seasonal uptake patterns with MCV4.Results: Coverage for MCV4 during 2005 among the 623,889 11-16 years olds was 10{\%}. Coverage for 11-12 and 14-15 year olds was 12{\%} and 11{\%}, respectively, compared with 8{\%} for 13- plus 16-year-olds (p < 0.001). Of the 64,272 MCV4 doses administered from March-December 2005, 73{\%} were administered June-August. Fifty-nine percent of all MPSV4 doses and 38{\%} of all Td doses were administered during June-August.Conclusion: A surge in vaccine uptake between June and August was observed among adolescents for MCV4, MPSV4 and Td vaccines. The increase in summer-time vaccinations and vaccination of non-targeted adolescents coupled with supply limitations likely contributed to the reported shortages of MCV4 in 2005.",
author = "Lorick, {Suchita A.} and Daniel Fishbein and Eric Weintraub and Wortley, {Pascale M.} and Lee, {Grace M.} and Fangjun Zhou and Robert Davis",
year = "2009",
month = "11",
day = "3",
doi = "10.1186/1471-2334-9-175",
language = "English (US)",
volume = "9",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Uptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005

T2 - Demand, supply and seasonality

AU - Lorick, Suchita A.

AU - Fishbein, Daniel

AU - Weintraub, Eric

AU - Wortley, Pascale M.

AU - Lee, Grace M.

AU - Zhou, Fangjun

AU - Davis, Robert

PY - 2009/11/3

Y1 - 2009/11/3

N2 - Background: In February 2005, the US Advisory Committee on Immunization Practices recommended the new meningococcal conjugate vaccine (MCV4) for routine use among 11- to 12-year-olds (at the preadolescent health-care visit), 14- to 15-year-olds (before high-school entry), and groups at increased risk. Vaccine distribution started in March; however, in July, the manufacturer reported inability to meet demand and widespread MCV4 shortages were reported. Our objectives were to determine early uptake patterns among target (11-12 and 14-15 year olds) and non-target (13- plus 16-year-olds) age groups. A post hoc analysis was conducted to compare seasonal uptake patterns of MCV4 with polysaccharide meningococcal (MPSV4) and tetanus diphtheria (Td) vaccines.Methods: We analyzed data for adolescents 11-16 years from five managed care organizations participating in the Vaccine Safety Datalink (VSD). For MCV4, we estimated monthly and cumulative coverage during 2005 and calculated risk ratios. For MPSV4 and Td, we combined 2003 and 2004 data and compared their seasonal uptake patterns with MCV4.Results: Coverage for MCV4 during 2005 among the 623,889 11-16 years olds was 10%. Coverage for 11-12 and 14-15 year olds was 12% and 11%, respectively, compared with 8% for 13- plus 16-year-olds (p < 0.001). Of the 64,272 MCV4 doses administered from March-December 2005, 73% were administered June-August. Fifty-nine percent of all MPSV4 doses and 38% of all Td doses were administered during June-August.Conclusion: A surge in vaccine uptake between June and August was observed among adolescents for MCV4, MPSV4 and Td vaccines. The increase in summer-time vaccinations and vaccination of non-targeted adolescents coupled with supply limitations likely contributed to the reported shortages of MCV4 in 2005.

AB - Background: In February 2005, the US Advisory Committee on Immunization Practices recommended the new meningococcal conjugate vaccine (MCV4) for routine use among 11- to 12-year-olds (at the preadolescent health-care visit), 14- to 15-year-olds (before high-school entry), and groups at increased risk. Vaccine distribution started in March; however, in July, the manufacturer reported inability to meet demand and widespread MCV4 shortages were reported. Our objectives were to determine early uptake patterns among target (11-12 and 14-15 year olds) and non-target (13- plus 16-year-olds) age groups. A post hoc analysis was conducted to compare seasonal uptake patterns of MCV4 with polysaccharide meningococcal (MPSV4) and tetanus diphtheria (Td) vaccines.Methods: We analyzed data for adolescents 11-16 years from five managed care organizations participating in the Vaccine Safety Datalink (VSD). For MCV4, we estimated monthly and cumulative coverage during 2005 and calculated risk ratios. For MPSV4 and Td, we combined 2003 and 2004 data and compared their seasonal uptake patterns with MCV4.Results: Coverage for MCV4 during 2005 among the 623,889 11-16 years olds was 10%. Coverage for 11-12 and 14-15 year olds was 12% and 11%, respectively, compared with 8% for 13- plus 16-year-olds (p < 0.001). Of the 64,272 MCV4 doses administered from March-December 2005, 73% were administered June-August. Fifty-nine percent of all MPSV4 doses and 38% of all Td doses were administered during June-August.Conclusion: A surge in vaccine uptake between June and August was observed among adolescents for MCV4, MPSV4 and Td vaccines. The increase in summer-time vaccinations and vaccination of non-targeted adolescents coupled with supply limitations likely contributed to the reported shortages of MCV4 in 2005.

UR - http://www.scopus.com/inward/record.url?scp=73949091648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949091648&partnerID=8YFLogxK

U2 - 10.1186/1471-2334-9-175

DO - 10.1186/1471-2334-9-175

M3 - Article

VL - 9

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

M1 - 175

ER -